Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1797 - Involvement of the immunoregulator MZB1 in progression of gastric cancer


09 Sep 2017


Poster display session


Translational Research;  Gastric Cancer




Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


Y. TANAKA, M. Kanda, C. Tanaka, D. Kobayashi, H. Tanaka, H. Takami, M. Hayashi, N. Iwata, Y. Niwa, S. Yamada, G. Nakayama, H. Sugimoto, M. Koike, M. Fujiwara, Y. Kodera

Author affiliations

  • Gastroenterological Surgery, Nagoya University Hospital, 466-8560 - Nagoya/JP


Abstract 1797


The initiation and progression of gastric cancer are associated with inappropriate immune responses caused by chronic inflammation of the gastric mucosa.


To identify immunoregulatory molecules involved in gastric cancer progression, transcriptome analysis was conducted using tissues from patients with metastatic gastric cancer. Gastric cancer cells lines and 200 pairs (cancerous and non-cancerous) of gastric tissues from patients with gastric cancer were analyzed for gene expression, amplification, DNA hypermethylation and functions of the candidate molecule.


The transcriptome analysis revealed that marginal zone B and B1 cell specific protein (MZB1) was expressed at significantly decreased levels in primary gastric cancer tissues when compared with the corresponding normal gastric mucosae. PCR array analysis exploring genes expressed cooperatively with MZB1 revealed that differential expression of MZB1 mRNA in gastric cancer cell lines correlated positively with the levels of the mRNAs encoding estrogen receptor 1 and desumoylating isopeptidase 1. Hypermethylation of the MZB1 promoter was frequent in cell lines with decreased levels of MZB1 mRNA. siRNA-mediated knockdown of MZB1 significantly increased proliferation, invasion and migration of gastric cancer cell lines. Low MZB1 expression was an independent prognostic factor for recurrence after curative gastrectomy and was associated significantly with increased haematogenous recurrence.


The immunoregulator MZB1 acts as a suppressor and serves as a predictor for recurrence after curative resection in gastric cancer.

Clinical trial identification

Legal entity responsible for the study

Mitsuro Kanda




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.